Navigation Links
95% Cure Rate for Prostate Cancer In Men Treated With HIFU (High Intensity Focused Ultrasound)
Date:3/5/2013

SARASOTA, Fla., March 5, 2013 /PRNewswire/ -- The Sarasota, Florida based Diagnostic Center for Disease™ in conjunction with PanAm HIFU, LLC, released data today showing a 95% cure rate with HIFU (High Intensity Focused Ultrasound) in more than 200 patients at more than 7 years post treatment. This group of patients had biopsy proven prostate cancer in conjunction with a 3.0 Tesla Magnetic Resonance Imaging Spectroscopy scan (MRI-S).  Ronald E. Wheeler, M.D. (Medical Director) attributes the results to excellence in imaging, excellence in application of technology as well as excellence in patient selection. While MRI-S continues to be evaluated in a head to head comparison to random prostate biopsies, it appears the MRI-S scan is the missing piece of the diagnostic puzzle allowing for a dramatic improvement in treatment results. Approximately 700,000 American men receive a negative prostate biopsy result; however approximately 25% of these results are false-negative. Under the current standard of care, prostate biopsy procedures collect 10-12 needle biopsy cores on average, effectively sampling less than 1% of a man's prostate. This approach leaves men at risk for a hidden cancer, leading to a high rate of repeat biopsies, often on cancer-free men, which hinders or delays the application of a procedure with this high rate of cure.

Specifically, the MRI-S scan allows for an enhancement of various diagnostic discrimination factors including: evidence of extracapsular extension (ECE), dominance of cancer in a side to side assessment, true density of tissue based on a diffusion weighted image sequence (DWI), dynamic contrast enhancement (DCE) and spectroscopy (if assessable). Once the patient assessment has taken place, a qualified HIFU treating expert can expect to experience predictably better results than those achieved without the MRI-S scan. Dr. Wheeler goes on to say that current worldwide data with HIFU (regardless of technology utilized) supports a cure rate of approximately 78-80%. Our data is a seminal study that enables prostate cancer patients the opportunity to improve their choice of one therapy versus another.

Interested patients are asked to call the clinic directly for more information at: 941-957-0007, or visit www.mrisusa.com or www.panamhifu.com.

This information is provided ahead of publication as a public health initiative.


'/>"/>
SOURCE Diagnostic Center For Disease
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ventana and Biocare Medical sign p63 license agreement to aid in the differential diagnosis of benign and malignant prostate lesions
2. U.S. FDA Grants Priority Review to Bayers Radium Ra 223 Dichloride NDA for Castration-Resistant Prostate Cancer with Bone Metastases
3. Fox News Medical Contributor Explains Study of Side Effects from Prostate-Cancer Treatments
4. Clinical Data from NewLink Genetics HyperAcute Prostate Cancer Immunotherapy Published in Journal of Immunotherapy
5. Prostate Cancer Study: Most Patients Report Satisfaction After Robotic Surgery
6. What Men Should Know About Prostate Cancer -- But Dont
7. Presentations at Leading Radiation Oncology Meeting Highlight CyberKnife Prostate Outcomes from Patients at More Than 40 Centers
8. Male Menopause, Testosterone, Prostate Cancer; The Connection Between Them
9. Prostate Cancer: The End of Life As Men Know It?
10. Urologists And Henry Schein Team Up To Urge Families To Put A Prostate Cancer Check-Up On The Back To School List For Dad
11. Leading Prostate Cancer Group Says New Drug Gives Hope To Men With Advanced Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
(Date:5/24/2016)... --   , ... Endpunkte und demonstriert Ebenbürtigkeit bei der Gesamtreinigung des ... guter , Reinigung des ... (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... der MORA-Studie der Phase III für NER1006 (1 ...
(Date:5/24/2016)... Celsion Corporation (NASDAQ: CLSN ... an update on its ongoing OVATION study, a ... the Company,s DNA-based immunotherapy, with the standard of ... advanced ovarian cancer who will undergo neoadjuvant chemotherapy ... IL-12 DNA plasmid vector formulated as a nanoparticle ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 27, 2016 , ... More than a third of American adults are considered ... surgery has received increased attention in recent years, as an article published ... weight loss, most people are familiar with the basic requirements of maintaining a healthy ...
(Date:5/27/2016)... ... ... With over 60 percent of acute stroke survivors being left unable to ... in the rehabilitation process has steadily increased. Ekso Bionics had been working to help ... stroke. , Ekso Bionics has now received clearance from the U.S. Food and Drug ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed ... by inspiring human interest stories, courtesy of leaders in the nursing and health ... the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research commissioned ... dogs straight off the grill. Of the 90 percent of Americans who say they ... hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving (9 ...
(Date:5/26/2016)... , ... May 26, 2016 , ... Connor Sports, ... basketball as a partner for the Tamika Catchings Legacy Tour that will ... industry leader in hardwood basketball surfaces in all forms and levels of the game, ...
Breaking Medicine News(10 mins):